Key statistics
On Friday, Roche Holding AG (RHO6:BER) closed at 38.80, -1.77% below its 52-week high of 39.50, set on Feb 14, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.50 |
---|---|
High | 39.50 |
Low | 38.80 |
Bid | 38.60 |
Offer | 39.70 |
Previous close | 39.50 |
Average volume | 179.20 |
---|---|
Shares outstanding | 6.47bn |
Free float | 342.99m |
P/E (TTM) | 28.61 |
Market cap | 266.75bn USD |
EPS (TTM) | 1.43 USD |
Annual div (ADY) | 1.24 EUR |
---|---|
Annual div yield (ADY) | 3.20% |
Div ex-date | Mar 14 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of Feb 14 2025 16:20 GMT.
More ▼
- FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
- New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
- FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
- Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
- [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
- Change to the Roche Enlarged Corporate Executive Committee
- Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
- Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
- Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
More ▼